Literature DB >> 24582477

Synthesis and evaluation of a novel class Hsp90 inhibitors containing 1-phenylpiperazine scaffold.

Jian-Min Jia1, Fang Liu1, Xiao-Li Xu1, Xiao-Ke Guo1, Fen Jiang1, Bahidja Cherfaoui1, Hao-Peng Sun2, Qi-Dong You3.   

Abstract

Previously, we identified 1-(2-(4-bromophenoxy)ethoxy)-3-(4-(2-methoxyphenyl)piperazin-1-yl)propan-2-ol (1) as a novel Hsp90 inhibitor with moderate activity through virtual screening. In this study, we report the optimization process of 1. A series of analogues containing the 1-phenylpiperazine core scaffold were synthesized and evaluated. The structure-activity relationships (SAR) for these compounds was also discussed for further molecular design. This effort afforded the most active inhibitor 13f with improved activity in not only target-based level, but also cell-based level compared with the original hit 1.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Hsp90 inhibitors; Structure-based drug design; Structure–activity relationships

Mesh:

Substances:

Year:  2014        PMID: 24582477     DOI: 10.1016/j.bmcl.2014.01.070

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  1 in total

1.  Impact of HSP90α, CEA, NSE, SCC, and CYFRA21-1 on Lung Cancer Patients.

Authors:  Wenwen Zhou; Yanhong Yang; Zhenzhen Wang; Yan Liu; Moslem Lari Najafi
Journal:  J Healthc Eng       Date:  2021-10-20       Impact factor: 2.682

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.